Sunesis Pharmaceuticals (SNSS) Expected to Post Earnings of -$0.29 Per Share

Wall Street brokerages predict that Sunesis Pharmaceuticals (NASDAQ:SNSS) will report earnings of ($0.29) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Sunesis Pharmaceuticals’ earnings, with estimates ranging from ($0.31) to ($0.27). Sunesis Pharmaceuticals posted earnings of ($0.47) per share in the same quarter last year, which suggests a positive year over year growth rate of 38.3%. The firm is expected to report its next quarterly earnings report on Monday, May 14th.

According to Zacks, analysts expect that Sunesis Pharmaceuticals will report full year earnings of ($1.04) per share for the current financial year, with EPS estimates ranging from ($1.09) to ($0.94). For the next fiscal year, analysts expect that the business will report earnings of ($1.16) per share, with EPS estimates ranging from ($1.16) to ($1.15). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Sunesis Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08.

SNSS has been the topic of a number of analyst reports. Oppenheimer initiated coverage on Sunesis Pharmaceuticals in a research report on Thursday, December 14th. They issued a “buy” rating and a $7.00 price target on the stock. Cantor Fitzgerald restated a “hold” rating and set a $4.00 target price on shares of Sunesis Pharmaceuticals in a research report on Thursday, March 8th. Wells Fargo upgraded Sunesis Pharmaceuticals from a “market perform” rating to an “outperform” rating and cut their target price for the company from $2.86 to $2.48 in a research report on Monday, December 11th. Zacks Investment Research lowered Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, February 15th. Finally, ValuEngine upgraded Sunesis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, February 7th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $4.00.

Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in shares of Sunesis Pharmaceuticals by 105.2% during the 4th quarter. Geode Capital Management LLC now owns 125,489 shares of the biopharmaceutical company’s stock valued at $463,000 after purchasing an additional 64,343 shares in the last quarter. Vatera Holdings LLC bought a new stake in shares of Sunesis Pharmaceuticals during the 4th quarter valued at about $673,000. BlackRock Inc. boosted its position in shares of Sunesis Pharmaceuticals by 9.5% during the 4th quarter. BlackRock Inc. now owns 130,573 shares of the biopharmaceutical company’s stock valued at $482,000 after purchasing an additional 11,351 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Sunesis Pharmaceuticals by 127.6% during the 3rd quarter. Wells Fargo & Company MN now owns 95,247 shares of the biopharmaceutical company’s stock valued at $185,000 after purchasing an additional 53,396 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Sunesis Pharmaceuticals by 4.1% during the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after purchasing an additional 23,819 shares in the last quarter. Institutional investors own 53.04% of the company’s stock.

NASDAQ SNSS opened at $2.48 on Friday. Sunesis Pharmaceuticals has a 12 month low of $1.82 and a 12 month high of $7.69. The stock has a market capitalization of $85.19, a price-to-earnings ratio of -1.71 and a beta of 1.81.

WARNING: “Sunesis Pharmaceuticals (SNSS) Expected to Post Earnings of -$0.29 Per Share” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3342696/sunesis-pharmaceuticals-snss-expected-to-post-earnings-of-0-29-per-share.html.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML).

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Head to Head Comparison: CrossAmerica Partners  vs. Aegean Marine Petroleum Network
Head to Head Comparison: CrossAmerica Partners vs. Aegean Marine Petroleum Network
Reviewing Owens Corning  & Carbo Ceramics
Reviewing Owens Corning & Carbo Ceramics
Analysts Set Emergent BioSolutions  PT at $52.75
Analysts Set Emergent BioSolutions PT at $52.75
-$0.02 Earnings Per Share Expected for ServiceSource  This Quarter
-$0.02 Earnings Per Share Expected for ServiceSource This Quarter
Analysts Set NextDecade  PT at $9.25
Analysts Set NextDecade PT at $9.25
Hilton Worldwide  Price Target Increased to $94.00 by Analysts at Deutsche Bank
Hilton Worldwide Price Target Increased to $94.00 by Analysts at Deutsche Bank


Leave a Reply

© 2006-2018 Ticker Report. Google+.